Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5552W HIGH $10.00
Volume
62.97 K
Value Traded
49.40 K
Short % Float
-
+7.56%Week
-6.61%1 Month
-40.52%3 Month
+22.19%6 Month
-94.23%5 Year
-94.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
37.86 M
EPS (TTM)
-0.37
P/E Ratio
-
Ent. Value
-10.54 M
Total Shares
48.22 M
Float Shares
-
Insiders
-
Institutions
2.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GNTA Catalyst Timeline
Dated clinical, regulatory and corporate events for Genenta Science S.p.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genenta Science S.p.A.
23Total events
0Upcoming
5Tier-1 (high impact)
2022 to 2026Coverage
Event history 23
▲Partnership / LicenseCorporate
Genenta signs definitive agreements to acquire 51% stake in Sophia High Tech
◆Corporate ApprovalCorporate
Shareholders' meeting scheduled to approve new corporate name Saentra Forge S.p.A. and new ticker SAEN
●Management ChangeCorporate
CEO Pierluigi Paracchi appointed to Board of Guarantors of Italian Academy at Columbia University
◆PublicationTemferonPresentation
Nature Medicine accepts manuscript on GBM trial findings; publication expected in coming weeks
Glioblastoma Multiforme (GBM)source ↗
▲Partnership / LicenseTemferonCorporate
Engaged DC Advisory as exclusive financial advisor for partnership initiatives for Temferon and cell therapy platform
glioblastoma multiforme (GBM)source ↗
▼Program DiscontinuationCorporate
Company does not plan to internally advance the GU study and other clinical trials at this time
▲Quarterly UpdateCorporate
Preliminary cash, cash equivalents, and marketable securities at Dec 31, 2025 approximately $33 million
◆Full ResultsTemferonClinical Data
Long-term survival trends and immune findings from TEM-GBM study
newly diagnosed glioblastoma multiforme (GBM) with unmethylated MGMT (uMGMT) gene promotersource ↗
◆Quarterly UpdateCorporate
Ordinary and Extraordinary Shareholders' Meeting on October 29, 2025 (first call) or October 30, 2025 (second call)
▼Equity OfferingCorporate
20 million ($20.9M) mandatory convertible bond financing from ENEA Tech and Biomedical
▲Trial InitiationTemferonTrial
Phase 1/2a trial in mRCC began enrolling patients
metastatic Renal Cell Carcinoma (mRCC)source ↗
◆Milestone PaymentCorporate
Second tranche of 12.5 million conditional upon safety and tolerability in mRCC trial
▲Topline ReadoutTemferonClinical Data
February 2025 data cutoff shows 29% two-year survival and 17 months median OS
Glioblastoma Multiforme (GBM) uMGMTsource ↗
◆Quarterly UpdateCorporate
Ordinary and Extraordinary Shareholders' Meeting to approve FY2023 financials, appoint board and auditors, amend bylaws
◆Enrollment CompleteTemferonTrial
Expect to complete enrollment and dosing in 2H 2023
glioblastoma multiformesource ↗
▲First Patient DosedTemferonTrial
Dosed patients in cohort 6 at 3.0 x 10^6 cells/kg
glioblastoma multiformesource ↗
◆Oral PresentationTemferonPresentation
Oral presentation at ASGCT 2022
glioblastoma multiformesource ↗
◆Oral PresentationTemferonPresentation
Presented at AACR and ASCO 2022
glioblastoma multiformesource ↗
Past FDA Catalysts and PDUFA Decisions
How GNTA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2008-12-03 | Genasense (oblimersen sodium) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every GNTA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Galimi FrancescoDirector, Officer (CMO& Head of Development) | Grant/Award | 20,000 20,000 held | $0.00 | 03/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GNTA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GNTA for Q2 2026. | ||||
GNTA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GNTA ranks across every disease it competes in
Competitive Position is a premium feature
See how GNTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGNTA News
GNTAGenenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
Sòphia High Tech has developed ROMAN, a robotic arm designed for remote inspection and maintenance of the RFX-mod2 fusion experiment. This initiative combines the company's precision manufacturing with the robotics expertise from the University of Naples Federico II and Herobots. The project aims to enhance operational efficiency in nuclear fusion research.
Read more →GNTAGenenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
Genenta-backed Sòphia High Tech reported strong fiscal year 2025 results, with sales rising 29.3% to €7.17 million and EBITDA increasing by 68.1% to €1.61 million. The total production value also saw a significant boost of 34.7% to €8.47 million. These results position the company for continued growth in the aerospace and defense sectors.
Read more →GNTAGenenta signs Definitive Agreements with Sophia High Tech enters aerospace as it continues its strategic transformation into a next-generation industrial consolidator
Genenta Science S.p.A. (Nasdaq: GNTA) has entered into definitive agreements with Sophia High Tech S.r.l. to acquire a controlling stake as part of its strategic transformation into Saentra Forge. This move aims to consolidate operations across multiple sectors, including aerospace and national security technologies. With an initial 19.9% stake and plans to increase to 51%, Genenta expects to enhance production capacity and profitability at Sophia HT, which reported solid financial performance in its recent fiscal year. The partnership will also involve overcoming regulatory hurdles and obtaining shareholder approval.
Read more →GNTA▼ -14.3%on this news
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
Genenta Science S.p.A., transitioning to Saentra Forge, has signed a binding offer with Sòphia High Tech, an Italian aerospace and defense manufacturer. The deal involves funding Sòphia through two capital increases, aiming for a controlling stake based on performance milestones. This strategic acquisition is expected to bolster Genenta's capabilities in critical sectors, including biotechnology and national security.
Read more →GNTAGenenta Science S.p.A. Registered office: Milan, via Dell'Annunciata 31 Subscribed and paid-up share capital of Euro 893,218.30 Tax code and registration number with the Milan Monza-Brianza Lodi Companies' Register: 0873
Genenta Science S.p.A. has announced the revocation of its previously scheduled Extraordinary Shareholders' Meeting, which aimed to discuss a proposed name change to Saentra Forge S.p.A. The Board's decision stems from the brand recognition and market presence that 'Genenta' has built over the past decade. Additionally, the company's ongoing development of its corporate purpose remains in the early stages. The Board continues to view the strategic adoption of a new name as an important goal moving forward.
Read more →GNTA▲ +8.2%on this newsshared move
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
Genenta Science S.p.A., transitioning to Saentra Forge, is exploring collaboration opportunities for its biotechnology platform. Despite not having active discussions with potential partners, the company remains committed to leveraging its scientific foundation. CEO Pierluigi Paracchi emphasizes the importance of retaining technological value in Italy while focusing on long-term shareholder interests.
Read more →GNTAGenenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
Genenta Science S.p.A., soon to be renamed Saentra Forge, announced the appointment of CEO Pierluigi Paracchi to the Board of Guarantors of the Italian Academy at Columbia University. This prestigious role aims to strengthen intellectual and cultural ties between Italy and the U.S. Paracchi emphasized the importance of connecting science, industry, and international collaboration.
Read more →GNTAGenenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on biotech and defense technologies. The company appointed Paolo Salvato to its Board of Directors to enhance governance in defense manufacturing. Additionally, Genenta is evaluating acquisition opportunities in national-security sectors and has a manuscript accepted for publication regarding its Glioblastoma Multiforme trial, indicating progress in its biotech initiatives.
Read more →GNTA▲ +18.5%on this news
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
Genenta Science S.p.A. is undergoing a strategic transformation to become Saentra Forge S.p.A., focusing on acquiring businesses in national security sectors. The company has initiated its first integration with ATC, a defense manufacturer, and plans to enhance its operations. Additionally, Genenta aims to leverage partnerships for its cell therapy platform while maintaining a strong financial position.
Read more →GNTA▲ +6%on this news· ran to +20% by day 3
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Genenta Science has reported consistent long-term survival metrics from its TEM-GBM study involving newly diagnosed glioblastoma multiforme patients. The study also reveals early immune responses to Temferon, indicating its potential effectiveness in the tumor microenvironment. However, these findings are preliminary and require further validation in larger trials. Genenta continues to maintain a strong financial position to support its ongoing research.
Read more →GNTA▼ -46.5%on this news· ran to -61% by day 1
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
Genenta Science announced a registered direct offering of 4,285,715 American Depositary Shares at $3.50 per share, raising approximately $15 million. The funds will be allocated for working capital and corporate purposes, supporting ongoing clinical trials, including for their proprietary therapy, Temferon. The offering is set to close by October 28, 2025, pending customary closing conditions. However, the company notes potential risks associated with these forward-looking statements and the investigational status of their therapies.
Read more →GNTAGenenta Science S.p.A. Consolidated Statements of Operations and Comprehensive Loss 2025 2024 Six Months Ended
Genenta Science S.p.A. released its consolidated statements of operations and comprehensive loss for the six months ending in 2025 and 2024. The document primarily details various accounting measures related to common stock, retained earnings, and comprehensive income. However, the text does not provide specific financial performance metrics or forward-looking statements that might indicate the company's operational health or strategic direction.
Read more →GNTAGenenta Science S.p.A. Registered office: Milano, via Olgettina n. 58 Share capital subscribed and paid equal to Euro 464.646,80 tax code and entry number on Milan Monza - Brianza Lodi Companies Register: 08738490963 NOT
Genenta Science S.p.A. has announced a notice for its ordinary and extraordinary shareholders' meeting scheduled for October 29, 2025. The meeting will be conducted exclusively via teleconference to discuss key agenda items, including the increase in the Board of Directors' membership. Shareholders eligible to vote must notify the company of their intention to attend and provide requisite documentation by October 24, 2025. This meeting aims to facilitate shareholder engagement and address governance enhancements.
Read more →GNTAGenenta Announces 20 million ($20.9M) Financing to Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Italy and New York, USA - March 19, 2025 - Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based
Genenta Science (Nasdaq: GNTA) has announced a financing deal worth $20 million to advance its pipeline, particularly its Temferon treatment for metastatic Renal Cell Cancer (mRCC). The funding, sourced through a Mandatory Convertible Bond from ENEA Tech and Biomedical (ETB), is set up to avoid immediate dilution of current shareholder equity. Meanwhile, recent data from the Phase 1/2a trial for Glioblastoma Multiforme shows improved survival rates, now at 29%, which reflects positively on the company's ongoing research. The bond investment is seen as a critical step towards supporting Genenta's clinical trials while also reinforcing its financial position.
Read more →GNTAGenenta Science S.p.A. Consolidated Statements of Operations and Comprehensive Loss 2024 2023 Six Months Ended
Genenta Science S.p.A. has released their consolidated statements of operations and comprehensive loss for the six months ended in 2024 and 2023. The article mainly lists financial terms and classifications without providing specific details regarding financial performance or results. This lack of detailed information could imply difficulties in reporting or overall business conditions.
Read more →GNTA▼ -7.5%on this news
Genenta Science S.p.A. Registered office: Milano, via Olgettina n. 58 Share capital subscribed and paid equal to Euro 371.685,80 tax code and entry number on Milan Monza - Brianza Lodi Companies Register: 08738490963 NOT
Genenta Science S.p.A. has announced a shareholders' meeting scheduled for April 29, 2024. The meeting aims to address key issues such as the approval of financial statements for 2023, the appointment of the Board of Directors and Statutory Auditors, and potential amendments to the bylaws. Participation will be remote, requiring shareholders to register in advance and provide necessary documentation. The final date for slates to be submitted is April 4, 2024.
Read more →GNTAGenenta Science S.p.A. Consolidated Statements of Operations and Comprehensive Loss 2023 2022 Six Months Ended
Genenta Science S.p.A. has published its consolidated statements for the operations and comprehensive loss for the six months ending in 2023 and 2022. The document raises concerns due to its complex presentation and lack of clear financial insights. Many entries pertain to related parties, which may complicate the evaluation of true financial health.
Read more →GNTAGenenta Science S.p.A. (formerly, Genenta Science S.r.l.) Consolidated Statements of Operations and Comprehensive Loss 2022 2021 Six Months Ended
GENENTA SCIENCE S.P.A. GNTA:CorporateCapitalMember us-gaap:AdditionalPaidInCapitalMember us-gaap:CommonStockMember us-gaap:RetainedEarningsMember GNTA:CorporateCapitalMember us-gaap:AdditionalPaidInCapitalMember us-gaap:CommonStockMember us-gaap:RetainedEarningsMember GN
Read more →GNTAGenenta Provides First Half 2022 Business Update and Financial Results
Provides First Half 2022 Business Update and Financial Results Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of 34.7 million as of Jun
Read more →About Genenta Science S.p.A.
BIOPHARMAWATCH ELITE PLUS
Trade the next GNTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime